Peptide Initiative

Peptides · Peptide comparison

Nesiritide (BNP) vs Thymosin Beta-4

Recombinant B-type natriuretic peptide that helps your heart breathe easier by reducing fluid overload and improving blood flow during acute heart failure crises.

The body's natural healing peptide that accelerates tissue repair and reduces inflammation

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeNesiritide (BNP)0.01–0.01 mcg/kg/minThymosin Beta-42–5 mg
FrequencyNesiritide (BNP)Once dailyThymosin Beta-4Twice weekly
AdministrationNesiritide (BNP)Intravenous (IV) bolusThymosin Beta-4Subcutaneous injection
Cycle lengthNesiritide (BNP)Ongoing/indefiniteThymosin Beta-48-12 weeks
Onset speedNesiritide (BNP)Moderate (1-2 weeks)Thymosin Beta-4Moderate (1-2 weeks)
Evidence levelNesiritide (BNP)Strong human trials (Phase 3 or FDA approved)Thymosin Beta-4Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Rapid Symptom Relief

Nesiritide (BNP)95%
Thymosin Beta-4No recorded rating

Fluid Management

Nesiritide (BNP)88%
Thymosin Beta-4No recorded rating

Heart Workload Reduction

Nesiritide (BNP)90%
Thymosin Beta-4No recorded rating

Wound Healing

Nesiritide (BNP)No recorded rating
Thymosin Beta-495%

Inflammation Reduction

Nesiritide (BNP)No recorded rating
Thymosin Beta-488%

Tissue Regeneration

Nesiritide (BNP)No recorded rating
Thymosin Beta-492%

Technical data

Compound specifications

Nesiritide (BNP)

Molecular formula
C143H244N50O42S4
Molecular weight
3464.0 Da
Half-life
18 minutes (terminal elimination half-life)
Bioavailability
100% (intravenous administration)
CAS number
114471-18-0

Thymosin Beta-4

Molecular formula
C212H350N56O78S
Molecular weight
4963
Half-life
Dose-dependent (increases with higher doses)
Bioavailability
100% (subcutaneous and intravenous)
CAS number
77591-33-4

Protocols

Dosing compared

Nesiritide (BNP)

Intravenous

  • 2 mcg/kg IV bolusSingle bolus at initiation · One-time loading doseFDA-approved Natrecor loading bolus given before the maintenance infusion [5][6]. May be omitted if hypotension risk is high.
  • 0.01 mcg/kg/min continuous infusionContinuous IV infusion · Typically up to 48 hoursFDA-approved maintenance infusion following the bolus [5][6]. Hospital-only with continuous blood-pressure monitoring.

Thymosin Beta-4

Subcutaneous injection

  • 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.

Topical ophthalmic (eye drops)

  • 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].

Intravenous injection

  • 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].

Applications

Best suited for

Nesiritide (BNP)

Emergency stabilization of acute heart failure episodes
Nesiritide (BNP) is particularly well-suited for individuals focused on emergency stabilization of acute heart failure episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Rapid relief of severe shortness of breath
Nesiritide (BNP) is particularly well-suited for individuals focused on rapid relief of severe shortness of breath. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Short-term relief in hospital, not long-term outcome improvement
Nesiritide's benefit is short-term: it lowers lung pressures and eases breathlessness in the first hours of treatment [5]. In the 7,141-patient ASCEND-HF trial it did not reduce 30-day death or heart-failure rehospitalization (9.4% vs 10.1%), and it is not recommended for routine use [2][5].
Managing sudden fluid buildup in the lungs or legs
Nesiritide (BNP) is particularly well-suited for individuals focused on managing sudden fluid buildup in the lungs or legs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Beta-4

Post-Surgery Recovery
Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
Chronic Wound Management
Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
Tissue Regeneration
Supports repair of damaged tissues from injury, burns, or degenerative conditions

Safety profile

Side effects

Nesiritide (BNP)

Common

  • Headache
  • Lightheadedness
  • Back pain

Uncommon

  • Hypotension (low blood pressure)
  • Abdominal pain
  • Insomnia

Serious

  • Acute kidney injury
  • Severe hypotension
  • Allergic reaction

Thymosin Beta-4

Common

  • Injection site redness
  • Injection site swelling

Uncommon

  • Temporary mild headache
  • Mild bruising at injection site
  • Transient fatigue

Serious

  • Allergic reaction

Research status

Safety & evidence

Nesiritide (BNP)

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Nesiritide (Natrecor) was FDA-approved for acutely decompensated heart failure with breathlessness at rest or minimal activity [5]. Low blood pressure is the dose-limiting side effect: 12% of patients versus 4% on placebo in long-infusion trials, and symptomatic hypotension in 7.1% versus 4.0% in the 7,141-patient ASCEND-HF trial [2][5]. When it happens it can last longer than with nitroglycerin (mean 2.2 vs 0.7 hours), because the blood-pressure effect outlasts the drug's 18-minute half-life [5]. Serum creatinine rises more often than with placebo or nitroglycerin, so kidney function is monitored during and after treatment [5]. A pooled analysis of seven trials found no increase in 30- or 180-day mortality, and the trials showed no evidence of tolerance (tachyphylaxis) to its effects [5].

Contraindications

  • Persistent systolic blood pressure below 100 mmHg before treatment [5]
  • Cardiogenic shock [5] or severe hypotension
  • Allergy to nesiritide or any ingredients [5]

Thymosin Beta-4

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.

Contraindications

  • Active systemic infections
  • Severe immunosuppression
  • Hypersensitivity to thymosin or any component
  • Pregnancy (insufficient safety data)

Decision guide

Which is right for you?

Nesiritide (BNP)

Choose Nesiritide (BNP) if…

  • Emergency stabilization of acute heart failure episodes
  • Rapid relief of severe shortness of breath
  • Reducing hospitalization time and improving outcomes
  • Managing sudden fluid buildup in the lungs or legs

Thymosin Beta-4

Choose Thymosin Beta-4 if…

  • Recovering from injuries or surgery
  • Improving wound healing speed
  • Reducing inflammation
  • Minimizing scar formation